Equities Analysts Offer Predictions for CORT FY2026 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities researchers at HC Wainwright raised their FY2026 earnings per share estimates for shares of Corcept Therapeutics in a research note issued on Monday, March 31st. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $3.99 per share for the year, up from their previous forecast of $3.80. HC Wainwright has a "Buy" rating and a $150.00 price objective on the stock. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics' FY2027 earnings at $7.46 EPS, FY2028 earnings at $9.29 EPS and FY2029 earnings at $11.10 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $181.89 million during the quarter, compared to analysts' expectations of $200.12 million.

Several other equities research analysts have also recently commented on CORT. Piper Sandler boosted their price target on Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a research note on Thursday, April 3rd. StockNews.com lowered shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, February 28th. Truist Financial raised their price target on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the company a "buy" rating in a report on Monday, March 31st. Finally, Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $143.25.

Remove Ads

Corcept Therapeutics Stock Down 4.9 %

CORT traded down $3.66 during trading on Thursday, reaching $70.99. 613,199 shares of the stock traded hands, compared to its average volume of 1,103,395. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $117.33. The stock's 50-day simple moving average is $65.10 and its two-hundred day simple moving average is $56.73. The stock has a market cap of $7.49 billion, a price-to-earnings ratio of 55.96 and a beta of 0.15.

Hedge Funds Weigh In On Corcept Therapeutics

Several large investors have recently bought and sold shares of the stock. Kestra Investment Management LLC bought a new position in shares of Corcept Therapeutics during the 4th quarter worth about $27,000. MassMutual Private Wealth & Trust FSB grew its position in Corcept Therapeutics by 102.0% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 620 shares of the biotechnology company's stock worth $71,000 after buying an additional 313 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in Corcept Therapeutics during the fourth quarter valued at about $40,000. National Bank of Canada FI acquired a new position in Corcept Therapeutics in the 4th quarter valued at approximately $42,000. Finally, USA Financial Formulas bought a new stake in shares of Corcept Therapeutics in the 4th quarter worth approximately $54,000. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Corcept Therapeutics news, CEO Joseph K. Belanoff sold 35,102 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $94.72, for a total value of $3,324,861.44. Following the sale, the chief executive officer now owns 2,982,335 shares of the company's stock, valued at $282,486,771.20. This trade represents a 1.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Sean Maduck sold 100,000 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $100.54, for a total value of $10,054,000.00. Following the completion of the sale, the insider now directly owns 85,622 shares of the company's stock, valued at $8,608,435.88. This represents a 53.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 163,124 shares of company stock valued at $15,074,318 over the last 90 days. 20.50% of the stock is currently owned by company insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.